Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A

Ratings ESG MSCI

Ratings Aarti Drugs Limited: Strengths and Weaknesses

  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: Aarti Drugs Limited
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Aarti Drugs Limited
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Rating Financials

Aarti Drugs Limited SectorIndia

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Aarti Drugs Limited SectorIndia

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Aarti Drugs Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Aarti Drugs Limited SectorIndia

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Aarti Drugs Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
38Cr -
A
- - -
93TCr
A
59TCr
BBB
41TCr
AA
38TCr
AA
33TCr
A
32TCr
AAA
30TCr
A
22TCr
A
20TCr
A
Average 36.7TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. AARTIDRUGS Stock
  4. Ratings Aarti Drugs Limited